Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.78 |
| ▸ | RARB | P10826 | 9/20 | 0.78 |
| ▸ | RARG | P13631 | 8/20 | 0.78 |
| ▸ | RXRG | P48443 | 12/20 | 0.59 |
| ▸ | RXRB | P28702 | 10/20 | 0.59 |
| ▸ | RARA | P10276 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15886820 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL727073 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8364736 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL4895819 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8366242 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL4905159 | 1.00 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8361331 | 0.85 | RXRA (0.58) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8361333 | 0.85 | RXRA (0.58) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL6862503 | 0.82 | RXRA (0.57) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL6862497 | 0.82 | RXRA (0.57) | RXRARARBRARGRXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | claimed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-7955852-B2 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. (IL) | 2011-06-07 | — | — | US | disclosed |
| EP-2305794-A1 | Expansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | disclosed |
| US-20050054097-A1 | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures | GAMIDA CELL LTD. (IL) | 2005-03-10 | — | — | US | disclosed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1161410-B1 | RETINOID ANTAGONISTS AND USE THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| US-6326397-B1 | OSTEOPOROSIS | HOFFMAN-LA ROCHE INC. | 2001-12-04 | — | — | US | disclosed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | RXRA, RXRG, RXRB | RXRA 1/4885RARB 10/4885RARG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.